An old topic with no clear answers - but looking to see if anyone has instituted a successful program for screening personnel potentially exposed to hazardous medications in the course of their job (pharmacy, nursing, others?) and what it consists of. Thanks!

Shannon Manzi, PharmD, BCPPS, FPPA
Director, Safety & Quality, Department of Pharmacy
Boston Children’s Hospital

Hi All, I am interested to know if you have been posed with the question of is it safe to use a mini-bag plus to reconstitute and administer the Regeneron monoclonal antibody (particularly in critical access sites). What are your thoughts?

Thanks in advance!
Merissa Andersen, PharmD, MPH, FISMP
Med Safety Officer- Mayo Clinic

Hi All, I am interested to know if you have been posed with the question of is it safe to use a mini-bag plus to reconstitute and administer the Regeneron monoclonal antibody (particularly in critical access sites).

Thanks in advance!
Merissa Andersen, PharmD, MPH, FISMP
Med Safety Officer- Mayo Clinic

Just trying to figure other hospitals practices with insulin pen vs. vials.

•Do you have any insulin pen that you use at your institution
•If yes, what pens do you use?
•If Yes, where do you store them? In Pharmacy or ADC?
•How do you label it?
•What Bar Code is used to administer mediations? Patient specific bar code or
NDC from the Pen.
*If you use vials, where do you store? Pharmacy or ADC?
*If you use vials, how do you dispense, draw up patient specific doses or nurse draw up doses on the floor?

Thanks for your help

After seeing the latest Med Safety Minute, I question what common procedures with insulin drips are here in the US. We only use insulin drips in three situations that I am aware of: 1) DKA, 2) HHS, and 3) BB/CCB Toxicity. I have heard that some utilize insulin drips for those on insulin U-500 instead of carrying the vials/pens. Interested in others.

Please reply with:

Does your institution use non-DEHP administration sets for lipids? If so, any special populations? PI says to consider using a non-DEHP set.

Hello All,
We are currently looking at implementing BCMA in Anesthesia. We are a Cerner hospital and have heard that there are issues scanning the patient-specific labels (vs product NDC) for pharmacy-compounded products. I would appreciate any insight into this as we try to move this process forward.

Hello All,

With a new restriction on pharmacist order verification due to allergy status being missing in the chart, the override pyxis list has been brought up for review.

One of the medications in question is Regular Insulin

We don't have any insulin on the override list

Patient Safety Pro's and Cons of having a short acting insulin on the override list

What do other hospitals do and what reasoning have you come to to allow or restrict its override

Thank You

Hello All, a decision has been made to place a HARDSTOP on pharmacist order verification when an "Unable to Obtain" is entered in the allergy field. Additionally, a pop-up generates when an order is inputted at the CPOE level.

A nurse reminder / order for review populates to remind the nurses that allergy documentation is missing.

Does any other facility place a HARDSTOP of pharmacist verification of orders due to an "Unable to Obtain" allergy status?

I am interested to see how other organizations are set up with their medication safety positions, and what their responsibilities are. Please consider answering the below questions.

How many FTEs does your organization have committed to medication safety?
How many hospitals do those FTEs oversee?
What is average number of beds in your hospitals?

Do your medication safety FTEs oversee any of the following?